Recent advances in iron metabolism and related disorders

Internal and Emergency Medicine

Volumn 5, Issue 5, 2010, Pages 393-400

  Camaschella, Clara ^a   Strati, Paolo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Hemochromatosis; Hepcidin; Hyperferritinemia; Iron deficiency; Iron metabolism

Indexed keywords

IRON;

HUMAN; IRON METABOLISM DISORDER; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

HUMANS; IRON; IRON METABOLISM DISORDERS;

EID: 77956874149     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0387-4     Document Type: Review

References (49)

1. Andrews NC, Schmidt PJ (2007) Iron homeostasis. Annu Rev Physiol 69: 69-85.
2. Rouault TA (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2: 406-414.
3. De Domenico I, McVey Ward D, Kaplan J (2008) Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 9: 72-81.
4. Nemeth E, Tuttle MS, Powelson J et al (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
5. Du X, She E, Gelbart T et al (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320: 1088-1092.
6. Silvestri L, Pagani A, Nai A et al (2008) The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 8: 502-511.
7. Tanno T, Bhanu NV, Oneal PA et al (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13: 1096-1101.
8. Finberg KE, Heeney MM, Campagna DR et al (2008) Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 40: 569-571.
9. Truksa J, Gelbart T, Peng H et al (2009) Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6. Br J Haematol 147: 571-581.
10. Trombini P, Coliva T, Nemeth E et al (2007) Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica 92: 1407-1410.
11. Iolascon A, De Falco L (2009) Mutations in the gene encoding DMT1: clinical presentation and treatment. Semin Hematol 46: 358-370.
12. Camaschella C (2009) Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol 46: 371-377.
13. Weinstein DA, Roy CN, Fleming MD et al (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100: 3776-3781.
14. Ganz T, Nemeth E (2009) Iron sequestration and anemia of inflammation. Semin Hematol 46: 387-393.
15. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H (2008) The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 60: 200-205.
16. Pietrangelo A (2004) Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 350: 2383-2397.
17. Goswami T, Andrews NC (2006) Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 281: 28494-28498.
18. Gao J, Chen J, Kramer M et al (2009) Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 9: 217-227.
19. Camaschella C (2005) Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106: 3710-3717.
20. Bacon BR, Britton RS (2008) Clinical penetrance of hereditary hemochromatosis. N Engl J Med 358: 291-292.
21. Fischer R, Piga A, Harmatz P, Nielsen P (2005) Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci 1054: 350-357.
22. Roetto A, Papanikolaou G, Politou M et al (2003) Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 33: 21-22.
23. Papanikolaou G, Samuels ME, Ludwig EH et al (2004) Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36: 77-82.
24. Camaschella C, Poggiali E (2009) Rare types of genetic hemochromatosis. Acta Haematol 122: 140-145.
25. Piperno A, Roetto A, Mariani R et al (2004) Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 89: 359-360.
26. Le Gac G, Mons F, Jacolot S et al (2004) Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 125: 674-678.
27. De Domenico I, Ward DM, Musci G, Kaplan J (2006) Iron overload due to mutations in ferroportin. Haematologica 91: 92-95.
28. Cazzola M (2005) Role of ferritin and ferroportin genes in unexplained hyperferritinaemia. Best Pract Res Clin Haematol 18: 251-263.
29. Lakhal S, Talbot NP, Crosby A, Stoepker C, Townsend AR, Robbins PA, Pugh CW, Ratcliffe PJ, Mole DR (2009) Regulation of growth differentiation factor 15 expression by intracellular iron. Blood 113: 1555-1563.
30. Tanno T, Porayette P, Sripichai O et al (2009) Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114: 181-186.
31. Mendler MH, Turlin B, Moirand R et al (1999) Insulin resistance-associated hepatic iron overload. Gastroenterology 117: 1155-1163.
32. Ruivard M, Lainé F, Ganz T et al (2009) Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 50: 1219-1225.
33. Riva A, Trombini P, Mariani R et al (2008) Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 14: 4745-4752.
34. Ajioka RS, Phillips JD, Weiss RB et al (2008) Down-regulation of hepcidin in porphyria cutanea tarda. Blood 112: 4723-4728.
35. Kannengiesser C, Jouanolle AM, Hetet G et al (2009) A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 94: 335-339.
36. Camaschella C, Poggiali E (2009) Towards explaining "unexplained hyperferritinemia". Haematologica 94: 307-309.
37. Clark SF (2009) Iron deficiency anemia: diagnosis, management. Curr Opin Gastroenterol 25: 122-128.
38. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J (2006) Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21: 378-382.
39. Angelucci E, Barosi G, Camaschella C et al (2008) Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 93: 741-752.
40. Maggio A, Vitrano A, Capra M et al (2009) Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 42: 247-251.
41. Cappellini MD, Taher A (2008) Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother 9: 2391-2402.
42. Sasu BJ, Cooke KS, Arvedson TL et al (2010) Anti-hepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. doi: 10. 1182/blood-2009-09-245977.
43. Kell DB (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2: 2. doi: 10. 1186/1755-8794-2-2.
44. Sullivan JL (2009) Iron in arterial plaque: a modifiable risk factor for atherosclerosis. Biochem Biophys Acta 1790: 718-723.
45. Zacharski LR, Chow BK, Howes PS et al (2007) Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 297: 603-610.
46. Ponka P (2004) Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann NY Acad Sci 1012: 267-281.
47. Berg D, Youdim MB (2006) Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 17: 5-17.
48. Thomas M, Jankovic J (2004) Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol 17: 437-442.
49. Camaschella C (2009) BMP6 orchestrates iron metabolism. Nat Genet 41: 386-388.